Pharmaceuticals, Biotechnology and Life Sciences
Summit Therapeutics has named its research and development adviser Dr David Roblin as new Chief Operating Officer (COO) and President of Research Development.
Hutchison China MediTech has appointed Paul Rutherford Carter as its Senior Independent Non-Executive Director, and a member of several its…
A UK-based maker of hair and skin care products InnovaDerma has been engaged in looking for an independent non-executive Director of the company, as Garry Lemair has decided to step down the board immediately, the company said on Tuesday.
An IT provider for healthcare market Instem, has appointed MaryBeth Thompson as Chief Operating Officer of the Group. Thompson has not been appointed to the company’s main Board, and she will report to Phil Reason, CEO.
Oxular Limited, a retinal therapeutics company, has promoted David Fellows, previously Non-Executive Director, as the Company’s Chairman of the Board. Fellows will replace Dr. Nigel Pitchford, who will continue on Oxular’s Board as a Director.
e-Therapeutics plc, the drug discovery company, has made further steps in transitioning its business as it picked Amgen Inc.’s Corporate Development Executive Director, Dr. Raymond Barlow as its new Chief Executive Officer (CEO) who assume his position before May 1, 2017.
Eli Lilly begins new year with reorganizing its leadership structure to pursue better growth opportunities in the upcoming years. The Chief Executive Officer of Lilly, David A. Ricks, who’s new position is also one among the latest promotions, said that the changes made to pharmaceutical therapeutics and geographic business should simplify and maximize the company’s late-stage pipeline and new drugs, as well as to improve productivity.